These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11354395)

  • 41. [Treatment of Paget's disease of bone: diphosphonates or calcitonin?].
    Davoine GA; Jung A; Courvoisier B
    Schweiz Med Wochenschr; 1981 Apr; 111(15):518-24. PubMed ID: 6785879
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML; Leonard M; Licata AA
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease.
    MacGowan JR; Pringle J; Morris VH; Stamp TC
    Skeletal Radiol; 2000 May; 29(5):279-82. PubMed ID: 10883448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
    Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
    Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapeutic effects of risedronate on Paget's disease of bone].
    Takata S
    Clin Calcium; 2006 Sep; 16(9):1508-12. PubMed ID: 16951476
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Current options for the treatment of Paget's disease of bone].
    Audran M
    Presse Med; 1996 Oct; 25(29):1317-9. PubMed ID: 8966189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paget's disease of bone: reduction of disease activity with oral risedronate.
    Hosking DJ; Eusebio RA; Chines AA
    Bone; 1998 Jan; 22(1):51-5. PubMed ID: 9437513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonate resistance in Paget's disease of bone.
    Joshua F; Epstein M; Major G
    Arthritis Rheum; 2003 Aug; 48(8):2321-3. PubMed ID: 12905487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.
    Liel Y; Abu Tailakh M
    Endocrine; 2019 Mar; 63(3):651-656. PubMed ID: 30406885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.
    Dewis P; Prasad BK; Anderson DC; Willets S
    Ann Rheum Dis; 1985 Jan; 44(1):34-8. PubMed ID: 3918513
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
    Kherani RB; Papaioannou A; Adachi JD
    Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biochemical response to combination of disodium etidronate with calcitonin in Paget's disease.
    O'Donoghue DJ; Hosking DJ
    Bone; 1987; 8(4):219-25. PubMed ID: 3128315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Paget's disease and bisphosphonates.
    Liel Y
    N Engl J Med; 2005 Dec; 353(24):2616-8; author reply 2616-8. PubMed ID: 16354901
    [No Abstract]   [Full Text] [Related]  

  • 55. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
    Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another.
    Gutteridge DH; Ward LC; Stewart GO; Retallack RW; Will RK; Prince RL; Criddle A; Bhagat CI; Stuckey BG; Price RI; Kent GN; Faulkner DL; Geelhoed E; Gan SK; Vasikaran S
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():79-84. PubMed ID: 10510219
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Paget disease of bone: therapeutic options.
    Silverman SL
    J Clin Rheumatol; 2008 Oct; 14(5):299-305. PubMed ID: 18838910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paget's Disease of Bone: Diagnosis and Treatment.
    Kravets I
    Am J Med; 2018 Nov; 131(11):1298-1303. PubMed ID: 29752905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.